Bedside Snapshot
- Normal (Adult)
- ≥90 mL/min/1.73 m² (≥1.5 mL/s/1.73 m²)
60–89 without kidney damage is not CKD; labs flag <60 as low - Critical Values
- No universal critical value: interpret by trend and clinical context. <15 is kidney failure (G5); a fall of >20% on repeat testing needs evaluation.
- High Suggests
- Normal or high GFR (G1)
- Pregnancy (hyperfiltration)
- Low muscle mass or cirrhosis: falsely high
- Early AKI before creatinine rises
- Low Suggests
- AKI: shock, sepsis, obstruction, nephrotoxins
- CKD (G3a–G5 for ≥3 months)
- High muscle mass, creatine, meat meal: falsely low
- Trimethoprim or cimetidine
- Act Now If
- eGFR <15 or an abrupt fall with K⁺ ≥6.5 mEq/L, ECG changes, severe acidosis, pulmonary edema or uremic signs: monitor, 12-lead ECG, IV calcium for ECG changes; urgent nephrology for dialysis
- Watch Out For
- eGFR assumes stable creatinine. Early in AKI it overestimates kidney function: judge by the creatinine trend and urine output, and dose renally cleared drugs with caution.
Reference & Critical Ranges
Lab-specific ranges: Every lab sets its own range, and the analyzer and the population both shift it. Use the range on your lab report. The numbers below are typical only.
Reference ranges
| Population | Conventional | SI | Notes |
|---|---|---|---|
| Adult (≥18 years) | ≥90 mL/min/1.73 m² | ≥1.5 mL/s/1.73 m² | CKD-EPI 2021 creatinine equation (race-free). Labs flag <60 as low; 60–89 without markers of kidney damage is not CKD |
| Older adult | Same thresholds | Same thresholds | Values of 60–89 are common; KDIGO 2024 keeps the <60 CKD threshold at every age. Low muscle mass makes creatinine-based eGFR read high |
| Pregnancy | Equations not validated | — | Glomerular hyperfiltration lowers creatinine, so adult eGFR equations do not apply; interpret creatinine with obstetric and nephrology input |
| Child and adolescent (2–17 years) | ≥90 mL/min/1.73 m² | ≥1.5 mL/s/1.73 m² | Use a height-based pediatric equation; KDIGO 2024 flags <90 as low in children over 2 years |
| Neonate and infant (<2 years) | Lower than adult, rising with age | — | GFR rises over the first 1–2 years (up to age 4); adult categories do not apply. Use age-specific interpretation |
Severity & critical values
| Level | Conventional | SI | What it means |
|---|---|---|---|
| G1: normal or high | ≥90 mL/min/1.73 m² | ≥1.5 mL/s/1.73 m² | CKD only if a marker of kidney damage (albuminuria, hematuria, imaging or biopsy finding, transplant) has lasted ≥3 months |
| G2: mildly decreased | 60–89 | 1–1.48 | CKD only with a marker of kidney damage; common in healthy older adults |
| G3a: mildly to moderately decreased | 45–59 | 0.75–0.98 | CKD if it persists ≥3 months, with or without damage markers; check renally cleared drug doses |
| G3b: moderately to severely decreased | 30–44 | 0.50–0.73 | Higher risk of complications (anemia, acidosis, hyperkalemia, bone disease) and of contrast-associated AKI |
| G4: severely decreased | 15–29 | 0.25–0.48 | Specialist kidney care referral; plan for kidney replacement therapy (KRT) |
| G5: kidney failure | <15 | <0.25 | KRT (dialysis or transplant) or conservative kidney care, decided by symptoms, complications and goals rather than the number alone |
| Critical | No universal critical value: interpret by trend and clinical context | — | Typical; lab-specific. <15 is kidney failure; a fall of >20% on repeat testing exceeds expected variability and needs evaluation |
Critical values: There is no universal critical value. Read the trend and the clinical picture (typical; lab-specific). An eGFR <15 is kidney failure (G5). Any abrupt fall is acute kidney injury (AKI) until proven otherwise. K⁺, acid–base status, volume and uremic signs set the urgency.
Conversion: mL/min/1.73 m² × 0.0167 = mL/s/1.73 m²; creatinine mg/dL × 88.4 = µmol/L. KDIGO 2024 wants labs to report eGFR in mL/min/1.73 m².
CKD-EPI 2021 creatinine equation (adults ≥18 years, no race term)
eGFR = 142 × min(SCr/κ, 1)α × max(SCr/κ, 1)−1.200 × 0.9938age × 1.012 [if female]
SCr in mg/dL; κ = 0.7 (female) or 0.9 (male); α = −0.241 (female) or −0.302 (male)
SCr in mg/dL; κ = 0.7 (female) or 0.9 (male); α = −0.241 (female) or −0.302 (male)
Normal is ≥90 mL/min/1.73 m². Here's the worked example: a 50-year-old man with creatinine 1.0 mg/dL has an eGFR of about 92. Double his creatinine to 2.0 mg/dL and the eGFR falls to about 40.
Causes of Abnormal Results
Low (eGFR <60 mL/min/1.73 m²)
A low eGFR is one of two things. Filtration really fell, acutely, chronically or both. Or creatinine rose and the GFR did not follow. CKD means <60 mL/min/1.73 m² (G3a–G5), or a marker of kidney damage, for at least 3 months. A new low in an acutely ill patient? That is AKI until proven otherwise.
| Mechanism | Common causes | Bedside clue |
|---|---|---|
| Low kidney perfusion (prerenal AKI) | Shock, hemorrhage, sepsis, vomiting, diarrhea, diuretics, heart failure | Hypotension, oliguria, BUN:creatinine ratio >20:1, rising creatinine |
| Intrinsic AKI | Acute tubular necrosis after sepsis or hypotension; nephrotoxins (NSAIDs, aminoglycosides, contrast in high-risk patients); rhabdomyolysis; glomerulonephritis; interstitial nephritis | Recent hypotension or nephrotoxin; dark urine with high creatine kinase (CK) in rhabdomyolysis; hematuria or red cell casts in glomerulonephritis |
| Postrenal obstruction | Prostatic enlargement, stones, blocked catheter, pelvic or retroperitoneal mass | Distended bladder, anuria, hydronephrosis on ultrasound |
| Chronic kidney disease (CKD) | Diabetic and hypertensive kidney disease, glomerular disease, polycystic kidney disease, prior AKI | Stable low values over months, albuminuria, small kidneys on imaging |
| Creatinine rise without a GFR fall (false low) | High muscle mass, creatine supplements, high-protein diet, a cooked meat meal, trimethoprim or cimetidine, assay interference (ketoacids or cephalosporins on Jaffe assays) | Well patient, normal urine output; cystatin C–based eGFR is higher |
Do not label a new low eGFR as CKD: One value cannot prove chronicity, and KDIGO 2024 says so. Pull the old results. Check urine output. Look for shock, sepsis, obstruction and nephrotoxins before you call it CKD.
High or higher than expected (eGFR ≥90 mL/min/1.73 m²)
| Mechanism | Common causes | Bedside clue |
|---|---|---|
| Normal or high GFR | Healthy young adults; pregnancy (glomerular hyperfiltration) | No markers of kidney damage; G1 alone is not CKD |
| Low creatinine generation (false high) | Frailty and sarcopenia, amputation, spinal cord injury, malnutrition, cirrhosis, eating disorders, low-protein or vegetarian diets | Low body mass or muscle wasting; creatinine well below the reference range; cystatin C–based eGFR is lower |
| Early AKI (non-steady state) | Any acute insult in the first hours to days | Oliguria or a rising creatinine trend while the single eGFR still looks normal |
A normal eGFR can hide danger: Early AKI and little muscle both make creatinine-based eGFR read higher than true GFR. Drugs cleared by the kidney, dosed off that number, can build up.
Interpretation & Bedside Approach
Step-by-step approach
- Is it valid? The estimate assumes creatinine is steady. In AKI and during recovery it trails the true GFR, so read the creatinine trend and urine output. Confirm an adult equation was used only at ≥18 years. Then ask whether a meat meal, a supplement or assay interference explains the number.
- How sick is the patient? Look for shock, oliguria, K⁺ ≥6.5 mEq/L or ECG changes, severe acidosis, pulmonary edema and uremic signs: confusion, pericardial rub, bleeding. Those set the urgency. The eGFR value does not.
- Acute or chronic? Find a baseline and compare. KDIGO 2024 says chronicity needs ≥3 months. In CKD, a change of >20% on a later test, or >30% after starting a hemodynamically active drug (ACE inhibitor, ARB, SGLT2 inhibitor), is more than expected variability. A trend tells you more than one value.
- Pick the right estimate. Start with the creatinine-based eGFR. Add cystatin C (eGFRcr-cys) when muscle mass or diet is unusual, or when a decision hangs on the number. Go to measured GFR when even that is not accurate enough.
- Classify with named criteria. Stage AKI with the KDIGO 2012 creatinine and urine-output criteria (rise ≥0.3 mg/dL within 48 hr, ≥1.5 × baseline within 7 days, or urine <0.5 mL/kg/hr for 6 hr). Not with eGFR, except stage 3 in patients <18 years (eGFR <35). CKD gets its label from KDIGO 2024 Cause, GFR category and Albuminuria category, e.g. "diabetic CKD G3b A2".
- Act on the decision the number feeds. Drug doses, contrast plans, referral and KRT planning all hang on it. See the table below and Management Priorities.
Which kidney-function estimate?
| Estimate | Use for | Caveat |
|---|---|---|
| eGFRcr: CKD-EPI 2021 equation | Routine adult screening, staging and most drug dosing | Muscle mass, diet and creatinine secretion bias it; invalid when creatinine is changing |
| eGFRcr-cys (creatinine + cystatin C) | Confirming CKD, extremes of body habitus, amputation, spinal cord injury, class III obesity, decisions that hinge on GFR | Most accurate estimate in ambulatory adults; less reliable in frailty, high inflammation, catabolism or high-dose steroids |
| eGFRcys (cystatin C only) | Otherwise healthy people with abnormal creatinine generation (amputees, body builders, eating disorders) | Raised by thyroid dysfunction, glucocorticoid excess, smoking, adiposity and inflammation |
| Cockcroft-Gault CrCl | Drug labels that specify creatinine clearance (enoxaparin, direct oral anticoagulants) | Pre-standardization creatinine, weight-dependent; not for CKD staging |
| Measured GFR (iohexol, iothalamate clearance) | Kidney donor evaluation, narrow-therapeutic-index chemotherapy, cirrhosis or heart failure when treatment depends on GFR | Specialist centers only; timed urine creatinine clearance is a less accurate fallback |
Cockcroft-Gault creatinine clearance (mL/min)
CrCl = (140 − age) × weight (kg) ÷ (72 × SCr in mg/dL) × 0.85 if female
There is no body-size index here. Use the weight the drug label or local policy names.
Non-indexed eGFR (mL/min) for drug dosing at extremes of size
eGFR (mL/min) = eGFR (mL/min/1.73 m²) × BSA (m²) ÷ 1.73
For narrow-therapeutic-range drugs in very small or very large patients, KDIGO 2024 suggests the non-indexed value.
Albuminuria categories (the second CKD axis)
| Category | Urine ACR | Meaning |
|---|---|---|
| A1 | <30 mg/g (<3 mg/mmol) | Normal to mildly increased |
| A2 | 30–300 mg/g (3–30 mg/mmol) | Moderately increased |
| A3 | >300 mg/g (>30 mg/mmol) | Severely increased; referral if persistent at ≥300 mg/g with hematuria, or >700 mg/g |
ACR is the urine albumin-to-creatinine ratio. Risk of kidney failure, cardiovascular events and death climbs as the GFR category drops and as the albuminuria category rises.
Management Priorities
Emergency: Kidney failure with life-threatening complications (eGFR <15 or an abrupt fall with K⁺ ≥6.5 mEq/L or ECG changes, severe acidosis, pulmonary edema or uremic signs)
- Monitor and assess: cardiac monitor, 12-lead ECG, blood gas, K⁺, glucose, volume status and urine output (bladder scan or catheter if obstruction is possible).
- Treat the complication: hyperkalemia per the potassium page (IV calcium for ECG changes, then shift and remove K⁺); support oxygenation and ventilation for pulmonary edema.
- Stop further injury: restore perfusion, relieve obstruction and stop potentially nephrotoxic drugs (NSAIDs, aminoglycosides) and metformin.
- Escalate: urgent nephrology. KDIGO 2012 calls for emergent kidney replacement therapy for life-threatening fluid, electrolyte or acid–base problems, judged on the whole picture rather than a single creatinine or BUN threshold.
Medication and contrast decisions by eGFR
| Decision | eGFR threshold | What to do |
|---|---|---|
| Metformin (FDA label) | <30; 30–45; <45 | Contraindicated below 30; do not start at 30–45; reassess benefit and risk if it falls below 45, stop below 30 |
| Metformin and iodinated contrast | FDA label: 30–60; KDIGO 2024: ≤30 or AKI | FDA label: stop at or before contrast if eGFR 30–60, liver disease, alcohol use disorder, heart failure or intra-arterial contrast; recheck eGFR at 48 hr. KDIGO 2024 stops it only with AKI or eGFR ≤30. Follow local policy |
| IV iodinated contrast (ACR–NKF 2020) | <30 or AKI; 30–44 | IV normal saline prophylaxis is indicated with AKI or eGFR <30 when not on maintenance dialysis; it may be considered at 30–44 in individual high-risk patients |
| Gadolinium MRI contrast | <30 or AKI | Prefer American College of Radiology group II (or III) agents; most nephrogenic systemic fibrosis cases followed group I agents |
| SGLT2 inhibitors, per KDIGO 2024 | ≥20 to start | Start in CKD with type 2 diabetes, ACR ≥200 mg/g or heart failure; may continue below 20 until KRT; hold during prolonged fasting, surgery or critical illness |
| ACE inhibitor or ARB, per KDIGO 2024 | Any, including <30 | Continue unless creatinine rises >30% within 4 weeks of starting or increasing the dose, or for symptomatic hypotension or uncontrolled hyperkalemia |
| Renally cleared drugs | Per label | Use the measure the label names: enoxaparin and direct oral anticoagulants use Cockcroft-Gault CrCl; level-guided drugs (vancomycin) follow levels |
Never delay life-saving imaging for an eGFR: KDIGO 2024 cautions against withholding contrast for a potentially fatal condition on the basis of GFR alone. Image first. Plan prophylaxis and drug holds around the study.
Definitive care & disposition
- Specialist kidney care (KDIGO 2024, adults): eGFR <30; a sustained fall >20% (or >30% after starting a hemodynamically active drug); a 5-year kidney failure risk >3–5% on a validated equation such as the Kidney Failure Risk Equation (KFRE); persistent ACR ≥300 mg/g with hematuria or >700 mg/g; red cell casts; refractory hypertension; persistent K⁺ abnormalities.
- KRT planning: a 2-year kidney failure risk >40% triggers modality education, vascular access and transplant referral.
- Children: refer any sustained decrease in eGFR to pediatric nephrology.
- Admission: AKI with hyperkalemia, acidosis, volume overload, uremic signs or a need for dialysis needs a facility with nephrology and dialysis capability.
Doses are typical references. Follow local protocols, medical direction and institutional policy.
Special Populations
| Population | What changes | Clinical implication |
|---|---|---|
| Neonates & infants | GFR is low at birth and rises over the first 1–2 years; Jaffe creatinine is distorted by bilirubin and hemolysis | Adult equations and categories do not apply; use enzymatic creatinine and neonatal drug-dosing references |
| Children & adolescents | Height-based equations: CKiD U25 2021 (the likely first choice per KDIGO 2024) or bedside Schwartz, 0.413 × height (cm) ÷ SCr (mg/dL); <90 flagged low after age 2 | Any sustained fall needs pediatric nephrology; KDIGO 2012 AKI stage 3 includes eGFR <35 under 18 years. See weight-based dosing |
| Pregnancy | Hyperfiltration lowers creatinine; eGFR equations are not validated | A creatinine that looks normal for a nonpregnant adult can be abnormal; involve obstetrics and nephrology |
| Older adults | Same CKD thresholds; sarcopenia lowers creatinine and ACR denominators | eGFRcr overestimates GFR and can lead to overdosing; consider eGFRcr-cys for drug decisions |
| CKD and kidney transplant | A transplant is itself a KDIGO marker of kidney damage; eGFR is staged as usual | Compare with the patient's own baseline; a >20% fall needs evaluation |
| Liver disease | Cirrhosis lowers creatinine generation | eGFRcr overestimates; eGFRcys is less biased, but measure GFR when treatment depends on it |
| Other | Amputation, spinal cord injury, body builders, class III obesity; testosterone therapy raises creatinine; race is not used in the CKD-EPI 2021 equation | Use cystatin C–based estimates; for transgender patients, KDIGO 2024 advises shared decision-making on which sex input or cystatin C to use |
Race-free eGFR: The NKF-ASN Task Force (2021) recommended that US labs drop the race term from the CKD-EPI 2021 equation. Without it, the equation slightly overestimates GFR in non-Black adults and underestimates it in Black adults. Adding cystatin C narrows both errors.
Interfering Factors & Pitfalls
Collection & handling
| Factor | Effect on eGFR | Why | Avoid / fix |
|---|---|---|---|
| Cooked meat or fish meal | ↓ (can be a meaningful fall) | Dietary creatinine raises SCr for several hours | For staging, draw at least 12 hr after a meat meal or repeat |
| Delayed separation (Jaffe assay) | ↓ | Measured creatinine rises in unseparated blood | Centrifuge within 12 hr of venipuncture |
| Hemolysis or icterus | Assay-dependent | Spectral and chemical interference | Enzymatic creatinine; recollect |
Medications & supplements
| Factor | Effect on eGFR | Why | Avoid / fix |
|---|---|---|---|
| Trimethoprim, cimetidine | ↓ (false) | Creatinine rises without a true GFR change | Expect a small rise; confirm with cystatin C if decisions depend on it |
| Creatine supplements, high-protein diet | ↓ (false) | More creatinine generation | Ask about supplements and diet |
| Cephalosporins, acetaminophen, aspirin, ascorbic acid | Assay-dependent | Reported interference with Jaffe creatinine | Ask the lab which method it uses |
| N-acetylcysteine, lidocaine metabolites | Assay-dependent | Reported interference with enzymatic creatinine | Interpret during infusions with caution |
| Glucocorticoids (high dose) | eGFRcys ↓ (false) | Cystatin C rises with glucocorticoid excess | Prefer creatinine-based or measured GFR |
Physiologic / biologic
| Factor | Effect on eGFR | Why | Avoid / fix |
|---|---|---|---|
| Rising or falling creatinine (AKI, recovery) | ↑ early, ↓ late (lags) | Equations assume a steady state | Use creatinine trend and urine output |
| Low muscle mass | ↑ (false) | Less creatinine generation | eGFRcys or eGFRcr-cys |
| Ketoacids in diabetic ketoacidosis (DKA), hyperglycemia | ↓ (false, Jaffe) | Acetoacetate and glucose react as creatinine | Enzymatic assay; recheck after treatment |
| Thyroid dysfunction, inflammation, smoking, adiposity | eGFRcys error | Non-GFR determinants of cystatin C | Interpret cystatin C with caution |
Assay & device-specific
| Factor | Effect on eGFR | Why | Avoid / fix |
|---|---|---|---|
| Different equation between reports | Apparent ↑ or ↓ | MDRD, CKD-EPI 2009 (race-based) and CKD-EPI 2021 differ | Compare like with like; check the equation on outside results |
| Missing or nonbinary sex field | Not reported | Equations need a sex input | Calculate manually or use cystatin C |
Common misinterpretations
- Normal creatinine = normal kidneys: An 80-year-old woman with creatinine 1.1 mg/dL still has an eGFR of about 51.
- eGFR 60–89 = CKD: Only with a marker of kidney damage that has lasted ≥3 months. The number alone does not make CKD.
- eGFR is precise: At best, about 90% of estimates land within 30% of measured GFR. So a true GFR of 60 can read 42–78.
- eGFR stages AKI: KDIGO AKI staging runs on creatinine change and urine output, not on eGFR, except under 18 years.
Physiology & Test Basics
What it measures
eGFR is an estimate, worked out from a formula. It tells you the volume of plasma both kidneys filter per minute, adjusted to a 1.73 m² body surface. Creatinine, BUN and the BUN:creatinine ratio are covered on their own pages.
Physiology & regulation
- Creatinine: Muscle turns creatine into creatinine at a fairly steady pace. The glomerulus filters it freely, and tubules secrete some too.
- Inverse curve: GFR and creatinine move in opposite directions, but not in a straight line. A small creatinine rise from a low baseline means a large loss of GFR.
- Non-GFR determinants: Muscle mass, diet, tubular secretion and extrarenal elimination shift creatinine with no change in GFR.
- Cystatin C: A second filtration marker that depends less on muscle. Put both markers together and you get the most accurate estimate.
- Development: GFR climbs through the first 1–2 years of life. It can keep rising until about age 4.
How it is measured
- Specimen: Serum or plasma creatinine, pulled from the basic or comprehensive metabolic panel or the renal panel. The tube depends on your lab. No separate order is needed.
- Reporting: Your lab does the math and rounds to a whole number in mL/min/1.73 m². It flags adult values <60. KDIGO 2024 favors enzymatic, standardized creatinine assays.
- Cystatin C: It is ordered separately but measured on the same sample as creatinine. That is what lets eGFRcr-cys get calculated.
- Point of care: A few cartridge analyzers give creatinine and eGFR at the bedside.
Why it matters
eGFR stages CKD and flags patients at risk of contrast-associated AKI and drug accumulation. It also sets the cutoffs for metformin, SGLT2 inhibitors and many renally cleared drugs. In acute care, the comparison with baseline is the payoff. The trap is trusting it while creatinine is still moving.
Clinical Pearls
Double the creatinine, roughly halve the GFR: Take a 50-year-old man. Creatinine goes from 1.0 to 2.0 mg/dL, and eGFR falls from about 92 to about 40. A "small" rise off a normal baseline is a big loss of filtration.
Hourly urine output beats a single eGFR (Nursing): Oliguria (<0.5 mL/kg/hr for 6 hr) meets KDIGO AKI criteria while creatinine is still too low to move the eGFR. Chart intake, output and daily weight.
Know the error bar: At best, eGFR lands within ±30% of measured GFR about 90% of the time. When a decision sits right on the line at 30 or 45, ask for cystatin C.
Read the label's kidney measure: Enoxaparin and the direct oral anticoagulant labels use Cockcroft-Gault CrCl. Metformin uses eGFR. In very small or very large patients, remove the body-size index and read eGFR in mL/min before dosing a narrow-range drug.
The expected dip (ED/ICU): Expect a small eGFR fall after you start an ACE inhibitor, ARB or SGLT2 inhibitor. It is not a reason to stop. A fall of >30% needs evaluation. KDIGO 2024 suggests holding these drugs (and metformin) during acute illness or before surgery. Write down the restart plan.
Hand off the baseline (Transport): The same creatinine of 2.0 mg/dL can mean stable CKD in one patient and stage 2 AKI in another. Bring prior results and draw times, so the receiving team can tell them apart.
Known CKD or AKI: avoid NSAIDs (EMS and Transport): Ketorolac labeling rules it out in advanced renal impairment and in patients at risk of renal failure from volume depletion. Flag the known baseline creatinine or eGFR at handoff. Then nobody gives an NSAID by default.
DKA and Jaffe creatinine: On Jaffe assays, ketoacids can push creatinine up falsely. The admission eGFR in DKA may look worse than true filtration. Recheck after treatment, before you label AKI or adjust doses.
References
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group; Stevens, P. E., Ahmed, S. B., Carrero, J. J., et al. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. (2012). KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements, 2(1), 1–138. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf
- Inker, L. A., Eneanya, N. D., Coresh, J., et al. (2021). New creatinine- and cystatin C–based equations to estimate GFR without race. New England Journal of Medicine, 385(19), 1737–1749. https://doi.org/10.1056/NEJMoa2102953
- Delgado, C., Baweja, M., Crews, D. C., et al. (2022). A unifying approach for GFR estimation: Recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. American Journal of Kidney Diseases, 79(2), 268–288.e1. https://doi.org/10.1053/j.ajkd.2021.08.003
- Davenport, M. S., Perazella, M. A., Yee, J., et al. (2020). Use of intravenous iodinated contrast media in patients with kidney disease: Consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology, 294(3), 660–668. https://doi.org/10.1148/radiol.2019192094
- Zydus Pharmaceuticals USA Inc. (2026). Metformin hydrochloride tablets: Prescribing information (sections 2.3, 2.4 and 4). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c82a10fa-1e8e-46b6-890a-737de3f34ee1
- Schwartz, G. J., Muñoz, A., Schneider, M. F., et al. (2009). New equations to estimate GFR in children with CKD (landmark derivation of the bedside Schwartz equation). Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
- Cockcroft, D. W., & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine (landmark derivation). Nephron, 16(1), 31–41. https://doi.org/10.1159/000180580
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.